BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E14.78 EPS (ttm)19.63 Insider Own0.10% Shs Outstand144.40M Perf Week1.51%
Market Cap42.04B Forward P/E18.40 EPS next Y15.77 Insider Trans-7.14% Shs Float143.01M Perf Month5.57%
Income2.86B PEG- EPS next Q3.51 Inst Own88.60% Short Float / Ratio1.32% / 1.52 Perf Quarter3.44%
Sales10.36B P/S4.06 EPS this Y-58.10% Inst Trans0.83% Short Interest1.89M Perf Half Y35.42%
Book/sh88.47 P/B3.28 EPS next Y-7.90% ROA11.80% Target Price322.30 Perf Year32.09%
Cash/sh33.89 P/C8.56 EPS next 5Y-3.70% ROE24.50% 52W Range187.16 - 311.88 Perf YTD4.75%
Dividend- P/FCF18.73 EPS past 5Y-9.30% ROI15.30% 52W High-6.99% Beta0.22
Dividend %- Quick Ratio2.10 Sales past 5Y-0.80% Gross Margin77.20% 52W Low54.99% ATR6.38
Employees9610 Current Ratio2.50 Sales Q/Q-9.70% Oper. Margin23.70% RSI (14)55.86 Volatility1.70% 2.38%
OptionableYes Debt/Eq0.49 EPS Q/Q253.70% Profit Margin27.60% Rel Volume0.72 Prev Close291.92
ShortableYes LT Debt/Eq0.49 EarningsFeb 15 BMO Payout0.00% Avg Volume1.24M Price290.08
Recom2.20 SMA202.76% SMA500.45% SMA20021.85% Volume894,098 Change-0.63%
Oct-26-22Upgrade Goldman Neutral → Buy $220 → $370
Oct-13-22Upgrade Stifel Hold → Buy $223 → $299
Oct-07-22Upgrade Argus Hold → Buy $300
Sep-28-22Upgrade Robert W. Baird Neutral → Outperform $224 → $340
Sep-28-22Upgrade Mizuho Neutral → Buy $207 → $270
Sep-28-22Upgrade BMO Capital Markets Market Perform → Outperform $217 → $360
Apr-18-22Upgrade Wells Fargo Equal Weight → Overweight $235 → $265
Mar-08-22Downgrade Stifel Buy → Hold $304 → $223
Mar-03-22Upgrade RBC Capital Mkts Sector Perform → Outperform $227 → $248
Feb-04-22Reiterated Wolfe Research Peer Perform $244 → $217
Show Previous Ratings
Jan-27-23 09:57AM
Jan-26-23 07:22PM
06:30PM
07:30AM
05:54AM
10:37AM Loading…
Jan-25-23 10:37AM
05:57AM
Jan-24-23 06:00PM
12:10PM
Jan-20-23 04:04PM
11:21AM
09:23AM
05:34AM
Jan-19-23 06:18PM
06:15PM
09:20AM Loading…
09:20AM
05:25AM
Jan-18-23 10:10AM
Jan-16-23 12:33PM
Jan-15-23 07:30PM
Jan-14-23 10:03AM
Jan-12-23 06:00PM
Jan-11-23 09:38AM
05:30AM
Jan-10-23 06:30PM
04:48PM
05:55AM
05:36AM
05:15AM
Jan-09-23 07:20PM
06:15PM Loading…
06:15PM
04:27PM
10:04AM
08:19AM
05:00AM
Jan-08-23 09:00AM
Jan-07-23 09:00AM
03:51AM
Jan-06-23 11:30PM
06:56PM
05:16PM
04:43PM
04:07PM
04:04PM
03:40PM
03:30PM
03:02PM
02:44PM
02:41PM
02:37PM
02:30PM
02:27PM
02:18PM
02:18PM
02:13PM
10:41AM
09:53AM
08:00AM
Jan-05-23 04:15PM
02:14PM
08:03AM
08:02AM
07:30AM
Jan-04-23 08:00AM
07:30AM
Jan-03-23 07:18PM
06:00PM
05:02PM
02:47PM
12:37PM
Dec-31-22 05:52PM
Dec-29-22 07:18PM
06:38PM
06:20PM
03:33PM
01:05PM
01:04PM
05:30AM
Dec-28-22 06:00PM
05:56PM
12:05PM
07:45AM
Dec-23-22 12:53PM
11:00AM
10:05AM
09:53AM
06:33AM
06:30AM
04:59AM
Dec-22-22 07:00PM
06:30PM
01:59PM
Dec-21-22 05:50PM
Dec-19-22 07:30AM
Dec-18-22 09:04AM
06:45AM
06:00AM
Dec-15-22 05:50PM
Dec-14-22 11:39AM
Dec-13-22 10:39AM
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kramer RobinChief Accounting OfficerDec 08Option Exercise0.0035002,368Dec 12 06:04 PM
Izzar RachidHead of Alzheimer's DiseaseDec 02Option Exercise0.001,71003,395Dec 06 06:37 PM
Murphy NicoleHead of Pharm Ops and TechDec 02Option Exercise0.0013102,807Dec 06 06:33 PM
Gregory GingerEVP, Human ResourcesNov 14Sale300.115,6101,683,6175,711Dec 12 08:00 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecOct 27Sale280.705,5321,552,83239,396Oct 28 07:19 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise0.004,74607,801Sep 06 07:31 PM
BIOGEN INC.10% OwnerAug 30Sale5.27100,000526,52023,652,466Aug 31 07:03 PM
BIOGEN INC.10% OwnerAug 29Sale5.33400,0002,130,72023,752,466Aug 31 07:03 PM
Murphy NicoleHead of Pharm Ops and TechAug 01Option Exercise0.001,08002,919Aug 03 05:40 PM
Kramer RobinChief Accounting OfficerJul 01Option Exercise0.0025202,092Jul 06 07:33 PM
Izzar RachidHead of Alzheimer's DiseaseJul 01Option Exercise0.0050402,258Jul 06 07:28 PM
Vounatsos MichelChief Executive OfficerFeb 18Option Exercise0.006,191070,007Feb 23 04:21 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 18Option Exercise0.001,98105,404Feb 23 04:19 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 18Option Exercise0.0059401,929Feb 23 04:16 PM
Kramer RobinChief Accounting OfficerFeb 18Option Exercise0.0039601,854Feb 23 04:18 PM
Murphy NicoleHead of Pharm Ops and TechFeb 18Option Exercise0.0037101,768Feb 23 04:20 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 18Option Exercise0.001,98108,243Feb 23 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 18Option Exercise0.001,387011,835Feb 23 04:15 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 18Option Exercise0.001,485045,587Feb 23 04:14 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.002,280045,646Feb 15 04:17 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 12Option Exercise0.002,59708,044Feb 15 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,672011,422Feb 15 04:16 PM
Kramer RobinChief Accounting OfficerFeb 12Option Exercise0.0027501,594Feb 15 04:13 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 12Option Exercise0.0035101,457Feb 15 04:14 PM
Murphy NicoleHead of Pharm Ops and TechFeb 12Option Exercise0.0026301,489Feb 15 04:11 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.008,716070,465Feb 15 04:12 PM